Atahan, L. Et Al. 2010. Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study. SUPPORTIVE CARE IN CANCER , vol.18, no.6 , 691-698.

Atahan, L., YILDIZ, F., CENGİZ, M., Kaplan, B., ÖZKAN, M., YAZICI, G., ... GÜNDOĞ, M.(2010). Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study. SUPPORTIVE CARE IN CANCER , vol.18, no.6, 691-698.

Atahan, Lale Et Al. "Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study," SUPPORTIVE CARE IN CANCER , vol.18, no.6, 691-698, 2010

Atahan, Lale Et Al. "Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study." SUPPORTIVE CARE IN CANCER , vol.18, no.6, pp.691-698, 2010

Atahan, L. Et Al. (2010) . "Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study." SUPPORTIVE CARE IN CANCER , vol.18, no.6, pp.691-698.

@article{article, author={Lale Atahan Et Al. }, title={Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study}, journal={SUPPORTIVE CARE IN CANCER}, year=2010, pages={691-698} }